FIGURE 7.

MGL-ko mice are more tolerant to the hypometabolic effect of the CBR agonist CP 55,940. Mice were fasted for 12 h and then treated with carrier solution alone (control, a–c), with 0.05 mg/kg (d–f), and with 0.15 mg/kg (g–i) of CP 55,940 (solubilized in PBS containing 5% ethanol and 5% Emulphor®) by intraperitoneal injection. Subsequently, locomotor activity (a, d, and g), O₂ consumption (b, e, and h), and food intake (c, f, and i) were monitored for 2 h. Data are presented as mean ± S.D. (n = 6 for each genotype). *, comparison of wild-type and MGL-ko mice; #, comparison of agonist- and carrier-treated mice; *, #, p < 0.05; **, ##, p < 0.01; ***, p < 0.001.